{"id":41660,"date":"2018-03-19T17:15:39","date_gmt":"2018-03-19T16:15:39","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=41660"},"modified":"2018-03-26T17:04:13","modified_gmt":"2018-03-26T16:04:13","slug":"ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/","title":{"rendered":"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US"},"content":{"rendered":"<p class=\"standfirst\">If drug importation was allowed, nearly 40% of off-patent drugs with limited US competition could have enough competitors to help ensure low prices<\/p>\n<p><!--more-->The rising cost of prescription drugs in the US continues to be the focus of intense scrutiny. As patients find both new and long standing treatments inaccessible because they cannot afford them, the burden of overall US spending on pharmaceutical products is also troubling. In a recent poll of US adults, 61% of respondents said that lowering the cost of prescription drugs should be a \u201ctop priority.\u201d<sup>[1]<\/sup>\u00a0In 2016, the US spent $450bn (\u00a3323bn; \u20ac364bn) on prescription drugs, a number expected to increase to $610bn by 2021.<sup>[2]<\/sup><\/p>\n<p class=\"c4\">A large part of this spending is made up of patented drugs newly approved by the US Food and Drug Administration (FDA). One of these is the first drug seeming to cure hepatitis C, which at $84 000 per course of therapy brought attention to the shockingly high prices of many newly approved drugs. Public attention has also been paid to the rising prices of some older drugs, which, despite no longer being protected by patents, often lack the downward driving pressure of robust competition. In some cases, without competition, pharmaceutical entrepreneurs have been able to acquire <span class=\"c1\">the rights to drugs and dramatically raise their price, as was the case with Turing Pharmaceutical\u2019s acquisition of pyrimethamine (Daraprim).<\/span><\/p>\n<p class=\"c4\">To tackle this problem, the FDA recently published lists of off-patent drugs that have few competitors, with the aim of attracting rivals to enter the market for individual drugs.<sup>[3]<\/sup>\u00a0In addition, as we recommended in 2016,<sup>[4]<\/sup>\u00a0the FDA now plans to expedite the review of additional generic drug applications in the hope of increasing the level of generic competition for drugs with three or fewer manufacturers. One approach that could expand the competitive market for these products would be to import versions of these drugs sold in other countries with comparable regulatory standards.<sup>[5]<\/sup><\/p>\n<p class=\"c4\"><span class=\"c1\">Over the past few years, policymakers from both ends of the political spectrum\u2014such as senators Ted Cruz (Republican-Texas), Bernie Sanders (Independent-Vermont), and Amy Klobuchar (Democrat-Minnesota)\u2014have filed legislation relating to drug importation. Frustrated by the growing strain on government budgets, individual states\u2014including Maine, Vermont, and Utah\u2014have also tried to pass legislation that would facilitate importation for local patients.<\/span><\/p>\n<p class=\"c4\">Our recent study <a href=\"http:\/\/www.bmj.com\/content\/360\/bmj.k831\">published in <em><span class=\"c10\">The BMJ<\/span><\/em><\/a>\u00a0<span class=\"c1\">evaluates the potential impact of such a strategy on generic competition in the US. We found that if drug importation was allowed, nearly 40% of off-patent drugs with limited US competition could have enough competitors to help ensure low prices. Unexpected drugs shortages would also be less likely to occur. <\/span><\/p>\n<p class=\"c4\"><span class=\"c1\">Although there has been concern that importing drugs could endanger patients, a substantial proportion of drugs approved by the FDA and currently sold in the US are already manufactured abroad. Safe and reliable importation systems for this purpose can be designed.<\/span><\/p>\n<p class=\"c4\"><span class=\"c1\">As internists, prescription drugs are among the most critical tools in our arsenal, so their affordability constitutes one of the most significant social justice issues of our time. In both the hospital and clinic, we regularly care for patients who feel the pressure of balancing the cost of drugs with that of rent and food. Patients are repeatedly admitted to hospital struggling to breathe because they are unable to afford inhalers to treat their chronic obstructive pulmonary disease. There are other patients who find insulin\u2014originally isolated almost 100 years ago\u2014to be prohibitively expensive for treating their diabetes. Health departments are feeling the effects of expensive drugs: in a recent meeting, one of us heard how the city in which we work is struggling to pay for naloxone, a decades old, life saving antidote for opioid overdoses. Such stories are sadly common in the US.<\/span><\/p>\n<p class=\"c4\"><span class=\"c1\">Importing drugs is clearly not a silver bullet for the entire problem of expensive drugs, and many questions around how best to implement this strategy remain. If we are serious, however, about reining in prices, we can combine drug importation with other systemic solutions, such as allowing Medicare to negotiate drug prices with manufacturers and achieving more transparent pricing from pharmaceutical manufacturers and pharmacy benefit managers. Ultimately, as physicians, our prescriptions can only be effective if our patients can afford them.<\/span><\/p>\n<p class=\"c7\"><em><strong><span class=\"c10 c12\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-41664\" src=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/03\/ravi_gupta.jpg\" alt=\"\" width=\"125\" height=\"142\" \/><\/span><\/strong><\/em><\/p>\n<p class=\"c7\"><em><strong><span class=\"c10 c12\">Ravi Gupta <\/span><\/strong><span class=\"c0\">is an internal medicine intern in the Osler Medical Training Program at Johns Hopkins Hospital in the Urban Health track.<\/span><\/em><\/p>\n<p class=\"c7\"><strong><span class=\"c12\">Competing interests:<\/span><\/strong><span class=\"c1\">\u00a0None declared.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p class=\"c4 c6\"><em><strong><span class=\"c12 c10\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-41665\" src=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/03\/Kesselheim_Aaron.jpg\" alt=\"\" width=\"125\" height=\"142\" \/>Aaron Kesselheim<\/span><\/strong><span class=\"c0\">\u00a0is an associate professor of medicine at Harvard Medical School. He is also the director of the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women\u2019s Hospital.<\/span><\/em><\/p>\n<p class=\"c7\"><strong><span class=\"c12\">Competing interests:<\/span><\/strong><span class=\"c1\">\u00a0<a href=\"http:\/\/www.bmj.com\/content\/360\/bmj.k831\">See research study<\/a>. <\/span><\/p>\n<p class=\"c7\"><strong><span class=\"c13 c12\">References<\/span><\/strong><\/p>\n<p class=\"c7 c9\"><span class=\"c1\">1. Kirzinger A, Wu B, Brodie M. Kaiser <\/span>health tracking poll: health care priorities f<span class=\"c1\">or 2017. Kaiser Family Foundation 2017<\/span>. <a href=\"http:\/\/www.kff.org\/health-costs\/poll-finding\/kaiser-health-tracking-poll-health-care-priorities-for-2017\"><span class=\"c1\">www.kff.org\/health-costs\/poll-finding\/kaiser-health-tracking-poll-health-care-priorities-for-2017<\/span><\/a><\/p>\n<p class=\"c7 c9\"><span class=\"c1\">2. Iqvia Institute for Human Data Science. Medicines Use and Spending in the US. 2017<\/span>. <a href=\"http:\/\/www.iqvia.com\/institute\/reports\/medicines-use-and-spending-in-the-us-a-review-of-2016\"><span class=\"c1\">www.iqvia.com\/institute\/reports\/medicines-use-and-spending-in-the-us-a-review-of-2016<\/span><\/a><\/p>\n<p class=\"c7 c9\"><span class=\"c1\">3. US Food and Drug Administration. FDA in <\/span>b<span class=\"c1\">rief: FDA works to encourage and optimize drug competition with transparency. 2017<\/span>. <a href=\"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/FDAInBrief\/ucm589275.htm\"><span class=\"c1\">www.fda.gov\/NewsEvents\/Newsroom\/FDAInBrief\/ucm589275.htm<\/span><\/a><\/p>\n<p class=\"c7 c9\"><span class=\"c1\">4 Gupta R, Kesselheim AS, Ross JS. Prioritization of<\/span>\u00a0generic drug review: r<span class=\"c1\">eply. <\/span><em><span class=\"c0\">JAMA Intern Med<\/span><\/em><span class=\"c1\">\u00a02017;177(1):141-42.\u00a0<a href=\"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/article-abstract\/2594766?redirect=true\">https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/article-abstract\/2594766?redirect=true<\/a><\/span><\/p>\n<p class=\"c7 c9\"><span class=\"c1\">5 Bollyky TJ, Kesselheim AS. Can drug importation address high generic drug prices? Brookings<\/span>.<span class=\"c1\">\u00a02017<\/span>. <a href=\"http:\/\/www.brookings.edu\/research\/can-drug-importation-address-high-generic-drug-prices\"><span class=\"c1\">www.brookings.edu\/research\/can-drug-importation-address-high-generic-drug-prices<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>If drug importation was allowed, nearly 40% of off-patent drugs with limited US competition could have enough competitors to help ensure low prices [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/\">More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":41691,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18894],"tags":[],"class_list":["post-41660","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-authors-perspective"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US - The BMJ\" \/>\n<meta property=\"og:description\" content=\"If drug importation was allowed, nearly 40% of off-patent drugs with limited US competition could have enough competitors to help ensure low prices [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-19T16:15:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-03-26T16:04:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/03\/us_dollars_pills.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"540\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US\",\"datePublished\":\"2018-03-19T16:15:39+00:00\",\"dateModified\":\"2018-03-26T16:04:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/\"},\"wordCount\":902,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/03\\\/us_dollars_pills.jpg\",\"articleSection\":[\"Author's perspective\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/\",\"name\":\"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/03\\\/us_dollars_pills.jpg\",\"datePublished\":\"2018-03-19T16:15:39+00:00\",\"dateModified\":\"2018-03-26T16:04:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/03\\\/us_dollars_pills.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/03\\\/us_dollars_pills.jpg\",\"width\":540,\"height\":350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/03\\\/19\\\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/","og_locale":"en_US","og_type":"article","og_title":"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US - The BMJ","og_description":"If drug importation was allowed, nearly 40% of off-patent drugs with limited US competition could have enough competitors to help ensure low prices [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2018-03-19T16:15:39+00:00","article_modified_time":"2018-03-26T16:04:13+00:00","og_image":[{"width":540,"height":350,"url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/03\/us_dollars_pills.jpg","type":"image\/jpeg"}],"author":"BMJ","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"BMJ","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US","datePublished":"2018-03-19T16:15:39+00:00","dateModified":"2018-03-26T16:04:13+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/"},"wordCount":902,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/03\/us_dollars_pills.jpg","articleSection":["Author's perspective"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/","url":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/","name":"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/03\/us_dollars_pills.jpg","datePublished":"2018-03-19T16:15:39+00:00","dateModified":"2018-03-26T16:04:13+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/#primaryimage","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/03\/us_dollars_pills.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/03\/us_dollars_pills.jpg","width":540,"height":350},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/03\/19\/ravi-gupta-and-aaron-kesselheim-importing-drugs-a-solution-to-high-priced-generics-in-the-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"Ravi Gupta and Aaron Kesselheim: Importing drugs\u2014a solution to high priced generics in the US"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmj\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/41660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=41660"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/41660\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media\/41691"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=41660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=41660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=41660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}